Edible Brands Executive Says FDA’s CBD Policy Could Support a Supplement-Style Edibles Framework, but Broader Reform Is Still Needed

A newly announced FDA policy on certain hemp-derived CBD products is drawing support from Edible Brands, which says the agency’s enforcement approach could help validate a supplement-style arrangement for edibles in healthcare settings. Edible Brands is the parent company of Edible Arrangements and Edibles.com.

While the policy remains narrowly limited to specific Medicare-related circumstances, the company says it signals movement toward a more structured pathway for bringing hemp-derived edibles into a regulated, consumer-facing market.

The Food and Drug Administration’s updated enforcement posture is being viewed by some in the cannabis and hemp industry as a modest but notable step toward regulatory clarity, particularly for companies pushing for a national framework for hemp-derived CBD products.

Among those welcoming the move is Edibles.com, whose general manager and executive vice president, Thomas Winstanley, said the policy reflects growing federal recognition that hemp-derived cannabinoids can fit within a more standardized model if they are subject to clear rules.

“The FDA’s enforcement posture on hemp-derived CBD products represents a meaningful, if incremental, step toward regulatory clarity”, said Winstanley. “By signaling it does not intend to enforce certain provisions of the FD&C Act for products that are manufactured, labeled, and marketed in alignment with a dietary supplement framework, the agency is acknowledging a practical pathway for bringing these products into a more standardized, consumer-accessible model.”

Winstanley said that approach mirrors what many in the industry have been advocating for, including a system built around labeling requirements, safety standards and responsible marketing.

“This recognition of a supplement-style approach—grounded in clear labeling, safety standards, and responsible marketing—reflects the direction many stakeholders have long advocated”, he said. “It is an important signal that a regulated, national marketplace for hemp-derived cannabinoids is both achievable and appropriate.”

Still, he made clear that the FDA’s action does not create long-term certainty for the broader market, especially outside the narrow healthcare setting covered by the policy.

“At the same time, the policy remains narrowly scoped and stops short of establishing a durable framework for the broader market”, said Winstanley. “Without Congressional action to codify these principles, significant segments of the industry, including full-spectrum products, remain at risk despite growing consumer demand.”

He said Edibles.com supports the FDA’s latest move, but believes Congress will need to act if the industry is to get the broader regulatory stability it has been seeking.

“We commend the FDA for advancing a pragmatic, common-sense approach and for reinforcing the importance of safety and transparency”, he said. “We remain committed to working with policymakers to build a comprehensive, lasting regulatory structure that ensures consumer access while supporting responsible industry growth.”